abstract |
IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in linkage disequilibrium variants thereof Eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects with one or more risk alleles. |